All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
It was announced in a press release on 7 February 2018 that Verastem has submitted a New Drug Application to the US food and drug administration (FDA) for the use of duvelisib in the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and an accelerated approval for relapsed follicular lymphoma (FL).
Duvelisib is the first oral dual inhibitor of phosphoinositide-3-kinase-delta (PI3K-δ) and PI3K-γ that has been showing potential in the treatment of R/R CLL, indolent non-Hodgkin lymphomas (iNHL) and T-cell lymphomas. In 2016, a review article highlighted duvelisib as a new drug in FL with encouraging results in refractory patients.
At the 59th meeting of the American Society of Hematology (ASH) in Atlanta, December 2017, results from the phase III DUOTM trial presented that duvelisib met its primary endpoint as showing significantly longer progression-free survival (PFS) compared with ofatumumab. In an interview with Lymphoma Hub, associate professor Nicole Lamanna from the Columbia University Medical Center in New York, provided insight into this trial. She told the hub, “we expected maybe a little bit longer progression free survival,” however, it is definitely useful to have other agents in the armamentarium, “especially if they have less toxicity.” She added, “duvelisib may represent one additional drug that you can consider for your relapsed, refractory patients with chronic lymphocytic leukemia.”
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox